Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer

The following article from Practice Update discusses the JAVELIN Renal 101 clinical trial, which compares avelumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC). The article highlights the results of this particular trial and touches upon other combinations of vascular endothelial growth factor (VEGF) inhibitors with immunotherapy as having not just […]

read more

Promising avelumab plus axitinib data in renal cell carcinoma

The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr Toni Choueiri from the Dana-Farber Cancer Institute in Boston, US, discusses the data from the JAVELIN-101 study comparing the avelumab/axitinib combination with sunitinib in patients with previously untreated RCC. Dr Choueiri goes on to discuss where these data fit into the complex treatment paradigm of […]

read more

Historical outcomes in metastatic renal cell carcinoma

The following OncLive video interview with two leading renal cell carcinoma (RCC) experts, Dr Brian Rini, Cleveland Clinic Lerner College of Medicine, and Dr David McDermott, Harvard Cancer Center, summarises how the treatment and prognosis of metastatic RCC has changed over recent years, and looks forward to the advent of combination therapies in the future. Watch […]

read more

Palliative care and survivorship

Although the following article from Cancer Therapy Advisor is written from a US perspective, a lot of what is discussed is relevant to the UK and the National Health Service. Over recent years, palliative care has evolved to include symptom management, management of psychosocial and spiritual needs, coping support, information about the disease and treatment, medical […]

read more

Treatment-related hyperprogression

The following article from Cancer Therapy Advisor presents the arguments for and against hyperprogression of tumours following treatment with immunotherapy. Some doctors in the US will not treat patients with immune checkpoint inhibitors if their tumours have genetic changes or mutations in the MDM2 or epidermal growth factor receptor (EGFR) genes. These mutations have been found to be […]

read more

First immunotherapy combination of ipilimumab plus nivolumab recommended by CHMP

We have just learnt the news that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), is recommending approval of the ipilimumab plus nivolumab combination for previously untreated patients who have intermediate- or poor-risk advanced renal cell carcinoma (RCC). The CHMP positive opinion will now be reviewed by the European Commission (EC), […]

read more

Combination bevacizumab plus temsirolimus for second-line treatment of metastatic kidney cancer

A recent phase 2 study evaluated the combination of bevacizumab with temsirolimus in 39 patients with metastatic renal cell carcinoma (mRCC) after failure of first-line treatment with a vascular endothelial growth factor (VEGF) receptor inhibitor. After 6 months, 50.9% of patients were progression-free and median time to progression of the disease was 6.8 months. The […]

read more

Potential new treatment strategy for kidney cancer

A research study, published online in eLife, has provided new insight into the mechanisms behind the development of clear cell renal cell carcinoma (ccRCC), which could have implications for how ccRCC is treated. The researchers have discovered that changes or mutations in tumour suppressor genes (VHL, PBRM1, KDM5C, SETD2 and BAP1) responsible for slowing down […]

read more

Safety and efficacy of nivolumab plus TKI combinations in advanced kidney cancer

A phase 1 study has evaluated the safety and efficacy of nivolumab in combination with sunitinib and pazopanib in people with advanced renal cell carcinoma (RCC). Although there were good responses to the nivolumab plus sunitinib  and nivolumab plus pazopanib combinations and progression-free survival (PFS) was encouraging (12.7 and 7.2 months respectively), the side effect […]

read more

Can food supplements/nutraceuticals prevent cancer?

A review of the literature and clinical studies published in Cancer Therapy Advisor suggests there is currently no evidence that the use of multivitamins or general vitamin and/or antioxidant supplements reduces the risk of developing cancer. With respect to the use of single vitamins or plant supplements, most of the studies conducted so far have […]

read more
Showing 21 to 30 of 432 results
  TOP